Coeptis Therapeutics Holdings, Inc. (COEP)
NASDAQ: COEP · Real-Time Price · USD
10.92
0.00 (0.00%)
Jul 30, 2025, 4:00 PM - Market open

Company Description

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company.

The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, natural killer cell therapy technology.

Its product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological and solid tumors.

In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson’s Disease.

The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings logo
CountryUnited States
Founded2017
IndustryBiotechnology
SectorHealthcare
Employees7
CEODavid Mehalick

Contact Details

Address:
105 Bradford Road, Suite 420
Wexford, Pennsylvania 15090
United States
Phone724 934 6467
Websitecoeptistx.com

Stock Details

Ticker SymbolCOEP
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001819663
CUSIP Number19207C104
ISIN NumberUS19207A2078
Employer ID84-3998117
SIC Code2834

Key Executives

NamePosition
David MehalickCo-Founder, Chairman of the Board, Chief Executive Officer and President
Christine Elise SheehyCo-Founder and Vice President of Compliance and Corporate Secretary
Daniel Alexander YeraceCo-Founder, Vice President of Operations and Director
Brian Cogley M.B.A.Chief Financial Officer
Dr. Colleen Delaney M.D., M.Sc.Consultant

Latest SEC Filings

DateTypeTitle
Dec 14, 202215-12GSecurities registration termination
Nov 8, 202210-QQuarterly Report
Oct 28, 20228-KCurrent Report
Sep 30, 2022DEFM14AFiling
Sep 21, 20228-KCurrent Report
Sep 21, 2022DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Sep 19, 2022SC 13GStatement of acquisition of beneficial ownership by individuals
Sep 16, 2022PREM14AFiling
Sep 7, 2022253G2Acc-no: 0001493152-21-027927 (33 Act)
Sep 7, 20228-KCurrent Report